Amphotericin B Liposome - CSPC ZhongQi Pharmaceutical Technology
Alternative Names: Amphotericin B Liposome injection; AnfulikeLatest Information Update: 11 Oct 2023
Price :
$50 *
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antifungals; Antiprotozoals; Antipyretics; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Mycoses
Most Recent Events
- 01 Sep 2023 CSPC Zhongnuo Pharmaceutical completes a phase I bioequivalence trial in healthy volunteers in China (NCT05913921)
- 16 Jun 2023 Chemical structure information added.
- 02 Jun 2023 CSPC Zhongnuo Pharmaceutical Technology initiates a phase I bioequivalence trial (In volunteers) in China (IV, Infusion) (NCT05913921)